Form 4: EyePoint Pharmaceuticals Director Goran Ando Acquires Stock Options
SEC Form 4 Filing
Director Goran Ando acquired 41,500 stock options in EyePoint Pharmaceuticals on January 3, 2025.
Summary
- On January 3, 2025, Goran Ando, a director of EyePoint Pharmaceuticals, acquired 41,500 stock options.
- The options have an exercise price of $8.26.
- The options become exercisable on January 3, 2026, and expire on January 3, 2035.
- Following the transaction, Ando beneficially owns 41,500 derivative securities.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of an insider transaction. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the actions of company directors. It's common for directors to receive stock options as part of their compensation.
Key Dates
| Date | Description |
|---|---|
| 01/03/2025 | Date of transaction: Goran Ando acquired stock options. |
| 01/03/2026 | Options become exercisable. |
| 01/03/2035 | Options expiration date. |
| 01/07/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.